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A B S T R A C T
Controversy exists concerning the role of the long prolactin receptor (PRLR) in the progression of breast
cancer. By targeting pre-mRNA splicing, we succeeded in knocking down only the long PRLR in vivo, leaving
the short forms unaffected. Using two orthotopic and highly-metastatic models of breast cancer, one of
which was syngeneic (mouse 4T1) to allow assessment of tumor-immune interactions and one of which was
endocrinologically humanized (human BT-474) to activate human PRLRs, we examined the effect of long
PRLR knockdown on disease progression. In both models, knockdown dramatically inhibited metastatic
spread to the lungs and liver and resulted in increased central death in the primary tumor. In the syngeneic
model, immune inﬁltrates in metastatic sites were changed from innate inﬂammatory cells to lymphocytes,
with an increase in the incidence of tumor-speciﬁc cytotoxic T cells. Long PRLR knockdown in three-
dimensional culture induced apoptosis of tumor-initiating/cancer stem cells (death of 95% of cells displaying
stemcellmarkers in 15days).We conclude that the longPRLRplays an important role in breast cancermetastasis.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Prolactin and breast cancer
The PRLR is a compelling target in several cancers [1–3]. For breast
cancer, a substantial body of evidence supports an important role
in the progression of disease. For example, serum PRL levels in the
top quartile of the range considered normal are associated with an
increased incidence of breast cancer equivalent to that seen with
estrogen [4]; PRLRs are expressed at higher levels in cancerous
lesions versus normal tissue [5]; high circulating PRL is correlated
with high breast density, itself associated with a higher incidence
of breast cancer [6,7]; PRL is an autocrine survival and growth-
promoting factor in breast cancer cells and a paracrine factor
produced by mammary stromal cells [8,9]; increased autocrine PRL
expression in ductal epithelium leads to development of both es-
trogen receptor positive and estrogen receptor negative cancers in
experimental animals [10]; and knockout of the PRLR markedly
slows the development of tumors induced by viral oncogene
overexpression [11]. Furthermore, normal mammary stem cells have
been reported to express the PRLR [12], suggesting the possibility
that PRLRs may be present on cancer stem cells and that targeting
the PRLR therefore has the potential to be curative. Also of great
signiﬁcance is that up to 95% of primary tumors express the PRLR
[13] while approximately 75% express the estrogen receptor [14].
Thus, therapies targeting the PRLR could have greater utility than
those targeting the estrogen receptor, including use in patients with
estrogen receptor negative tumors and/or metastases.
Prolactin receptor forms and breast cancer
Themost abundant PRLR forms in the human andmouse include
a long and three short forms (SF1a-c in human [15,16] and S1-3 in
mouse [17]). Most work with most cancer types supports the con-
tention that the long PRLR promotes cell proliferation and survival,
while one of the short forms (SF1b in human) is anti-proliferative
and pro-apoptotic [1–3,18–22], a dominant negative. In breast
tumors, the ratio of long to short PRLRs is positively correlated with
progression of disease [22]. However, increased nuclear amounts
of Stat5, which is a downstream signaling molecule associated with
activation of the long PRLR, are associated with a better prognosis
in breast cancer [23], and in vitro studies have demonstrated that
activation of Stat5 enhances the epithelial versus mesenchymal phe-
notype of breast cancer cells [24]. Thus, there is some controversy
about the exact role of the long PRLR in breast cancer. The domi-
nant negative short PRLR inhibits function of the tumor-promoting
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form by hetero-dimerization [25]. In addition, the dominant neg-
ative down-regulates expression of the tumor-promoting receptor
[18] and, when homodimerized, signals to promote differentia-
tion and apoptosis [1,2,26]. Thus, preservation of the dominant
negative PRLR would be predicted to have signiﬁcant therapeutic
advantages.
Materials and methods
Study design
Following pilot experiments to separately assess variation in receptor knock-
down and tumor growth andmetastatic spread as a function of the number of tumor
cells implanted, a power analysis was performed to determine sample size. With
longer-term trials where there was a greater chance that some control animals would
succumb to their disease, the sample size was increased to ensure appropriate sample
size should some animals be lost to analysis. All treatment durations were pre-
determined and unaltered during the course of the study. Data from animals that
died before the tissue collection date were excluded from analysis. This was decided
prospectively. No outliers were removed from analyses. A total of 9 trials with, and
3 without, tumors were conducted. Replications are reported in the ﬁgure legends.
Breast cancer cell lines
Tumor cell lines were obtained from American Type Culture Collection (Manassas,
VA), which repository authenticates via short tandem repeat DNA proﬁling. Mouse
4T1 and human BT-474 were used for the in vivo analyses. Cells were routinely cul-
tured in RPMI 1640 with 10% fetal bovine serum (FBS) (Invitrogen/Life technologies,
Grand Island, NY). On the day of harvest, cells were removed from the culture plates
by incubation in 0.25% trypsin/2.21 mM EDTA for 5 min at 37 °C, pelleted, washed
in Dulbecco’s phosphate buffered saline (DPBS) and then suspended in serum-free
RPMI 1640 containing matrigel (BD Biosciences, San Jose, CA) such as to produce a
10mg/ml suspension used for orthotopic injection. Continuous culture in vitro results
in downregulation of the PRLR and hence only cultures up to 15 generations were
used.
Animals
Two strains of mice were used in the study, BALB/cJ and NOD SCID (NOD.CB17-
Prkdcscid/SzJ) (Jax mice, Bar Harbor, ME). Females aged 8–9 weeks at the time of
orthotopic cell placement were used. BALB/cJ mice are syngeneic with the 4T1mouse
breast cancer cell line and NOD SCID mice were used for human BT-474 tumors. In
both instances, tumor cells were placed within the mammary fat pad. The number
of implanted cells depended on the duration of desired exposure to treatment (see
ﬁgure legends) since, in these highlymetastatic models, death can occur in the control
animals before the desired duration of treatment in the experimental group is com-
plete. So as to preserve implanted cell and recipient tissue integrity, cell placement
in the mammary fat pad was achieved using a ½ inch 26 gauge needle and gentle
pressure during delivery of 50 μl cells. Animals were randomly assigned to exper-
imental groups. Animals from each experimental group were injected in turn to
randomize effects due to time since cell harvesting. In order to replicate normal ex-
posure to human PRL, and because mouse PRL does not interact with the human
PRLR [27], mice receiving BT-474 cells (both control SMO- and PRLR SMO-treated)
also received recombinant human PRL suﬃcient to result in a circulating level of
10–15 ng/ml (measured in trunk blood as described below). Recombinant human
PRL, prepared as previously described [28], was administered via inter-scapular sub-
cutaneous osmotic minipump (Alza Corporation, Cupertino, CA). At the end of the
treatment period, thewetweight of the tumorwas determined, the tumorwas divided
radially such that each piece was representative of the whole, and the pieces
were processed for histology, gene expression, or for extraction of immune cells. All
animal procedures were approved by the University of California, Riverside,
Institutional Animal Care and Use Committee and were in accordance with
guidelines from the American Association for Laboratory Animal Care. Animals were
housed under speciﬁc pathogen-free conditions with 12 hour light–dark cycles and
ad libitum access to food. Animals were checked daily for external indicators of ad-
vanced disease.
Splice-modulating oligomers
The splice-modulating oligomers (SMOs) (Table 1) were custom synthesized as
Vivo-Morpholinos by Genetools LLC (Philomath, OR). A scrambled, non-functional
oligomer with the same modiﬁcations was used as the control. All primers used for
RT-PCR are also provided in Table 1. Since focus was on the ability to inhibit me-
tastasis rather than to shrink a pre-existing tumor, treatment with the control or
PRLR SMO was begun 3 days prior to tumor cell implantation so that delivery of the
SMOs from an Alzet minipump was accurate at the time of tumor cell implanta-
tion. For longer treatments, a fresh pump was inserted at day 28.
RT-PCR and qPCR
Tissues were snap frozen and 50–100 mg extracted in RiboZol (Amresco, Solon,
OH). Cultured cells were washed once with DPBS before RiboZol was added to culture
wells. mRNAwas reverse-transcribed with oligo-dT (ﬁrst-strand cDNA synthesis using
M-MLVRT kit, Invitrogen). Analysis used a CFX96 qPCR Detection System (BioRad,
Hercules, CA) and SYBR greenmastermix reagent (iQ SYBR Green, BioRad). All samples
for qPCR were conﬁrmed to have only a single peak in the melting curve. All values
were normalized to glyceraldehyde-3 phosphate dehydrogenase (GAPDH) or β-actin
mRNA.
General histology/histopathology
Tissues were ﬁxed in 10% formaldehyde in DPBS, pH 7.4, dehydrated and em-
bedded in paraplast. Sections were stained with hematoxylin and eosin and assigned
a coded group number. Sections were examined by another individual without knowl-
edge of treatment group identity. Blood smears were produced at the time of
euthanasia, stained with Wright’s stain and subjected to a white cell count.
EdU and TUNEL staining
The nucleoside analog, 5-ethynyl-2′-deoxyuridine (EdU), was injected intra-
peritoneally (160 μg/g body weight) 2 hours before tissue harvesting. On tissue
sections, incorporated EdU was detected using the Click-IT™ system (Invitrogen/
Life technologies). TUNEL staining was accomplished using a DeadEnd kit from
Promega (Madison, WI). EdU and TUNEL staining was performed either on sec-
tions midway through the primary tumor if the whole tumor was used or on radial
sections from the middle to the outer edge if only a portion of the tumor was used
for histological analysis. Four sections per tumor were examined and photo-
graphed by confocal microscopy. The areas of the sections staining positively for EdU
or TUNEL were calculated. Only similarly-sized sections were used for quantitative
analysis in order to distinguish effects of tumor size from effects of the PRLR SMO
on the area of dead cells. Negative controls included staining of tumors from non-
EdU-injected animals, and processing without use of Terminal Deoxynucleotidyl
Transferase. Positive controls included section treatment with DNAse 1. Negative
control values were subtracted.
Table 1
SMO sequences and Primers used.
SMO sequence
Human PRLRSMO GCCCTTCTATTAAAACACAGACACA
Mouse PRLRSMO GCCCTTCTATTGAAACACAGATACA
Human primer sequence for q-PCR
Forward primers (5′–3′) Reverse primers (5′–3′)
LF-PRLR CCTTGTCCAGGTTCGCTGCAAA AGATGAGCATCAAATCCTTTTA
SF1b PRLR TAAATGGTCTCCACCTACCCTGAT CACCTCCAACAGATGAGCATCAAATCC
Beta-actin AAAGACCTGTACGCCAACAC GTCATACTCCTGCTTGCTGAT
Mouse – primer Sequence for q-PCR
LFPRLR ATAAAAGGATTTGATACTCATCTGCTAGAG TGTCATCCACTTCCAAGAACTCC
S1-PRLR AAGCCAGACCATGGATACTGGAG AACTGGAGAATAGAACACCAGAG
S2-PRLR TGCATCTTTCCACCAGTTCCGGGGC TCAAGTTGCTCTTTGTTGTCAAC
S3-PRLR TGCATCTTTCCACCAGTTCCGGGGC TTGTATTTGCTTGGAGAGCCAGT
GHR TCTCAAGGAAGGGAAGTTGGAG AGCTCAATGAACTCGACCCA
GAPDH TGCACCACCAACTGCTTAG GGATGCAGGGATGATGTTC
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Quantiﬁcation of metastases arising from 4T1 tumors
After mincing lung tissue, dissociation was accomplished with a collagenase/
elastase cocktail (1 mg/ml type IV collagenase and 6 units/ml elastase in Hank’s
buffered salt solution – HBSS) and incubation for 75min at 4 °C. Resultant cells were
washed in HBSS and plated in RPMI1640 medium containing 10% FBS and 60 μM
6-thioguanine for 14 days without disturbance of the cultures. Colonies arising from
metastatic tumor cells were gently washed free of normal cell debris, ﬁxedwithmeth-
anol, and stained with 0.03% (w/v) methylene blue for counting. The entire ﬂat region
of a 75mm ﬂask was microscopically examined and photographed, the images were
combined using Adobe Photoshop software, and the number and size of colonies
recorded.
Morphometric analysis of lung metastases arising from BT-474 tumors
For the BT-474 tumors, metastatic spread to the lung was assessed morpho-
metrically.Without knowledge of the groups, three sections from the equivalent region
of the lung of each animal were photographed in their entirety, the images were
combined and the area occupied by tumor cell densities on each section was mea-
sured using Adobe Photoshop software and expressed as a percentage of total section
area.
Isolation of immune cells from liver and ex vivo response to tumor antigens
Liver tissue was minced with a sharp blade, rinsed to remove blood cells in the
circulatory system, and pressed through a 70 μmmesh immersed in RPMI 1640. Cell
debris was removed by gentle pelleting and resuspension. 1–2 × 106 cells in RPMI
1640 (plus 10% FBS, penicillin (50 μg/ml) Streptomycin (50 u/ml)) were incubated
with a 4T1 tumor cell lysate in the presence of puriﬁed mouse anti-CD28 antibody
for 1 hour at 37 °C, after which BDGolgiStop (4 μl/6 ml cell suspension) was added
for 5 hours. Control cells were stimulated with anti-CD28, but not with tumor cell
lysate. Cells were then washed and ﬁrst stained with ﬂuorochrome-conjugated rat
anti-mouse CD8 or CD4 antibodies for effector T cells. After washing and
permeabilization with ﬁxation and permeabilization buffer (BD Biosciences), cells
were further stained for intracellular IFN-γ and IL-2 with ﬂuorochrome-conjugated
rat antibodies. When staining was complete, formaldehyde ﬁxed cells were ac-
quired in a BD FACSAria ﬂow cytometer and analyzed by FlowJo software. Antibodies
were all rat anti-mouse and, except for the Fc blocker, were used at 1:100 dilution.
Antibodies were obtained from BD Biosciences (Fc blocker clone 2.4G2 @ 1 μg/1–
2 × 106 cells; CD8a clone 53-6.7; CD4 clone RM4-5) or eBioscience (IL-2 clone JES6-
5H4; IFNγ clone XMG1.2).
Sphere-forming assay for tumor-initiating/cancer stem cells
4000 4T1 cells were cultured per well in non-attachment 6 well plates (Corning
#3471) in selection medium (serum-free DMEM/F12 with 2% B27, 20 ng/ml epi-
dermal growth factor, 20 ng/ml ﬁbroblast growth factor and 4 μg/ml heparin) [29]
for 7 days. Cells were treated with the control or PRLR SMO at 1 μM for 7 days.
Flow cytometric analysis of stemness
Two-dimensional: 5 × 105 4T1 cells were seeded per well in a 6 well plate and
incubated overnight to ensure attachment. Cells were then treated with the SMOs
(800 pmol in 2 ml), with replacement of this medium every 8 h for 2, 5, 9 and 15
days. At these time points, cells were collected using trypsin/EDTA (as above) and
stained with antibodies to determine mouse mammary stemness, deﬁned as Lin-
CD24 + CD29hi Aldh+ [30]. Three-dimensional: 4 × 103 4T1 cells were cultured as
for the sphere-forming assay for 7 days. The resultant spheres were dissociated with
trypsin/EDTA and then recultured under the same conditions in 1 μM control or PRLR
SMO in combinations to produce PRLR SMO exposure for 0, 2, 5, 9, and 15 days for
a total in each case of 15 days of treatment. At the end of the 15 day period, the
spheres were dissociated with Accutase (Sigma, St. Louis, MO) for 10 min at 37 °C,
and stained for stem cell markers (as above) and for apoptosis (annexin V, 1:20 from
eBioscience). Aldehyde dehydrogenase was detected using an Aldeﬂuor kit (Stem
Cell Technologies, Vancouver, BC). Antibodies were rat anti-mouse from eBiosciences
(lineage cocktail, 1:5; CD24 clone 30-F1, 1:200; CD29 clone HMb1-1, 1:100).
Aminotransferase and hormone assays
Aminotransferases were measured in plasma by miniaturizing commercial kit
volumes (Bioo Scientiﬁc, Austin, TX). Prolactin was measured using the Nb2 bioas-
say, as described previously [28] using mouse (kindly provided by AF Parlow, Harbor–
UCLA Medical Center, Torrance, CA) or human PRL [28] as standard, as appropriate.
Pretesting for the presence of IL-2 and adsorption of plasma samples with antibod-
ies against IL-2 established that there was insuﬃcient IL-2 in the samples to affect
the assay. Addition of the PRLR or control SMO to the standard curve did not affect
the assay. Estradiol and Progesterone were assayed using commercial kits (Cayman
Chemical Co., Ann Arbor, MI).
Statistical analyses
The Mann–Whitney test was used for analysis of in vivo data when comparing
control and PRLR SMO-treated groups. For comparisons of more than two groups,
ANOVAwith posttests and Bonferroni corrections for multiple comparisons was con-
ducted. Two tailed analysis was used. The signiﬁcance of the Pearson correlation
coeﬃcient for responding CD8+ cells versus tumor weight was determined using a
table available at http://www.gifted.uconn.edu/siegle/research/correlation/
corrchrt.htm. All data where individual values are not shown are expressed as the
mean ± SD and a p value <0.05 was considered signiﬁcant.
Results
Speciﬁcity of the knockdown
To speciﬁcally knock down the long PRLR, a splice-modulating
oligomer (SMO), blocking splicing between intron 9 and exon 10
[15], was synthesized (sequences for mouse and human versions
in Table 1). At a dose of 100 pmol/h/mouse for 5 days, the PRLR SMO
reduced long PRLR expression by 75% or more in the mammary
gland, liver and ovary (Fig. 1A). The PRLR SMO had no effect on ex-
pression of any of the short forms of the PRLR (Fig. 1B) in this or
longer time frames, or on growth hormone receptors (Fig. 1C), the
latter despite the sometimes reciprocal expression between PRL and
growth hormone receptors reported in the literature [31]. With this
5-day treatment, knockdown of the long PRLR elevated circulat-
ing PRL (Fig. 1D), but elevated PRL was not a feature of longer-
term treatments (see later ﬁgure). Short-term treatment depressed
estradiol levels at all doses (from 14 ± 1 to 9 ± 0.6 pg/ml), and trended
toward increased progesterone, but, as was true for PRL, levels nor-
malized with longer-term treatment (normal at 14 days).
Inhibition of metastasis to the lung
The important contribution of immune cells to tumor toler-
ance [32] and metastatic spread [33], and the presence of PRLR on
multiple immune cells [34], prioritized evaluation of metastasis in
an immune-competent model. 4T1 mouse breast cancer cells are
highly spontaneously metastatic [35], and, following orthotopic
placement in syngeneicmice, their metastasis is considered to closely
mimic the spread of human breast cancer [35]. By examining meta-
static spread from orthotopic tumors, one can expect much larger
variability than would occur with tail vein administration. Never-
theless, after 40 days of PRLR SMO treatment, the number of
metastatic colonies in the lungs was clearly reduced. Comparing the
mean values in each group, inhibition was 80% versus control SMO
treatment. Not only was the number of colonies reduced but also
the size and density were reduced (Fig. 2A and B). Two control
animals died ahead of the planned day of analysis. It is likely that
their metastatic load was higher, but they were eliminated from the
analysis. Neither had any external indicators of more advanced
disease, as assessed by interactive behavior, coat quality, apparent
appetite, or reduced body weight. Knockdown of the receptor within
the tumor was conﬁrmed, whereas in the pituitary there was no
effect (Fig. 2C). At this time point, there was no effect on PRL levels
(Fig. 2D).
Altered immune inﬁltrates in the liver
Tumors of 4T1 cells initiate a profound granulocytic response [36].
Both granulocytes and macrophages contribute to an inﬂammato-
ry environment, which in turn can lead to a state of immune
tolerance to tumors [37]. Evaluation of liver metastatic spread dem-
onstrated an abundance of granulocytes and monocytes/
macrophages in the liver of control SMO-treated animals that was
not apparent in those treated with the PRLR SMO (Fig. 2E). The livers
of control SMO-, but not PRLR SMO-treated mice also showed
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evidence of inﬂammatory damage, as assessed by loss of sinusoi-
dal endothelial integrity and early hydropic change in hepatocytes
(Fig. 2E). In the absence of tumors, the SMOs had no effects on either
granulocyte numbers or distribution, or sinusoidal endothelial or
hepatocytemorphology (Supplementary Table S1 and Supplementary
Fig. S1).
By contrast, accumulating, liver-inﬁltrating white blood cells in
the PRLR SMO-treated animals were predominantly lymphocytes
(Fig. 2F). Lymphocyte inﬁltration in the absence of inﬂammatory
damage suggested a potential immunosuppressive effect of the PRLR
SMO, whichmay have been counterproductive for clearance of tumor
cells, but when immune cells (including all T regulatory cells present)
were isolated from liver inﬁltrates (i.e. cells outside of the sinu-
soids) and exposed ex vivo to homogenates of 4T1 cells, 8/8 PRLR
SMO-treated animals had CD8+ cells in the liver that responded to
tumor antigens compared to 2/6 control SMO-treated animals
(Table 2). As might be predicted, there was a larger CD8+ than CD4+
inﬁltrate, suggestive of an anti-tumor cytotoxic response. Further-
more, when ex vivo immune responses of each animal were
individually correlated with weights of primary tumors, the greater
the number of CD8+ cells responding in the treated animals, the
smaller the primary tumor (Fig. 2G, correlation = −0.53). Thus, these
tumor antigen-responsive T cells reﬂected functionality in vivo.
Despite this correlation, the effect on tumorwetweight was not large,
but as illustrated in the section “Bulk Tumor Cell Death in the Primary
Tumor,” there was a major effect on cell viability within the primary
tumor.
Inhibition of colony formation and apoptosis of tumor-initiating cells
in vitro
Given themajor effect of the PRLR SMO onmetastasis and the im-
portant role of tumor-initiating (cancer stem) cells in the
establishment of metastases, we asked whether the PRLR SMO af-
fected the colony-forming capacity or number of tumor-initiating cells.
Using cells in non-attachment three-dimensional culture, no spheres
were formed in the presence of the PRLR SMO (Fig. 3A and B). Using
surface markers to identify stem cells [38], their percentage in the
population was similar to the percentage that formed spheres. Their
number was reduced by the PRLR SMO as a function of time such
that by day 15, there was a 70% reduction in two-dimensional, and
a 95% reduction in three-dimensional, culture (Fig. 3C and D). At day
15 in three-dimensional culture, 70% of the remaining stem cells
stained positively with annexin V, illustrating that a large propor-
tion of the 5% remaining had initiated apoptosis (Fig. 3E). Depending
on the culture, the 4T1 stem cell population varied from 0.5 to 4%.
Almost 100% of these cells produced PRL and expressed the PRLR,
whereas the majority of bulk 4T1 cells did not (Supplementary
Fig. 1. Effect of the PRLR SMO on in vivo expression of the various PRLR types, growth hormone receptors, and circulating PRL. The PRLR SMO was administered to adult
female BALB/c mice at 1 (Low), 10 (Mid) and 100 (High) pmol/h/mouse for 5 days via Alzet minipump. Results shown are from quantitative RT-PCR using primers speciﬁc
for the LF PRLR (A), short forms of the receptor (B) or all forms of the growth hormone receptor (C). Effects on circulating PRL levels on day 5 are shown in D. *p < 0.05. n = 3
animals per dose in this range-ﬁnding experiment. A dose–response was conducted 3 times.
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Table S2). For this reason, the PRLR SMO had very little effect in vitro
in the absence of added PRL (Supplementary Fig. S2A and C). These
data also demonstrate a lack of in vitro toxicity in the normal HC11
cells up to 10 μM. However, because 12–19% of bulk 4T1 cells ex-
pressed the PRLR, the PRLR SMO completely blocked the increase in
4T1 cell number in response to PRL (Supplementary Fig. S2B). In vivo,
circulating mouse PRL would have interacted with all PRLR+ cells.
Bulk tumor cell death in the primary tumor
Analysis of the primary tumor showed that the area occupied
by TUNEL-positive cells was markedly increased by treatment with
the PRLR SMO (Fig. 3F, panel 6, green, and Fig. 3G). Conﬁrmation
of long PRLR knockdown in the primary tumors is shown in panel
H. This analysis was of tumors after 14 days of treatment. At later
Fig. 2. Effect of the PRLR SMO on lung and liver metastasis in the syngeneic model. Tumors were initiated by orthotopic placement of 3 × 103 4T1 cells. Treatment was with
control SMO or PRLR SMO for 40 days at 100 pmol/h/mouse. Results shown are quantiﬁcations of the number of metastatic colonies derived from the 6-thioguanine sur-
vival assay in the lung (A, where signiﬁcance was determined by the Mann–Whitney test), representative (closest to the mean) staining of these metastatic colonies showing
reduced cells per colony as well as reduced colonies (B), long PRLR expression in the pituitary, where there was no effect, and primary tumor where there was an effect at
day 40 (C), lack of effect on circulating PRL levels at day 40 (D), representative images from control (E) and PRLR SMO-treated (F) livers, and the negative correlation between
the percentage of tumor-speciﬁc CD8+ cells in the liver and primary tumor weight in the PRLR SMO-treated group (G) after 40 days of treatment-correlation −0.53 (see
Materials and Methods). *p < 0.05. n = 8 in the PRLR SMO group and n = 6 in the control group (Con). **Two animals in the control group succumbed to their metastatic load
prior to analysis. Bar = 1 cm in B and 45 μm in E and F. White and black arrows illustrate a granulocyte and monocyte, respectively. All analyses were conducted a minimum
of 3 times each except for the correlation analysis, which only occurred once. All data shown are from the same set of animals.
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time points, the central region of the PRLR SMO-treated tumors was
largely acellular (Supplementary Fig. S3).
Inhibition of metastasis in a xenograft model
To assess anti-metastatic activity in a human xenograft
model, we chose highly-metastatic human BT-474 breast cancer cells,
widely-used for assessment of Herceptin’s effects on metastasis
[39]. To humanize this model from an endocrine standpoint,
NOD-SCID mice were given human PRL (hPRL) to ensure normal
use of PRLRs on the tumor cells in vivo. The level of hPRL
replicated the upper quartile of normal (10–15 ng/ml), a level
associated with increased breast cancer in the human population
Table 2
Percentages of tumor antigen-reactive T cells in the liver.
Animal
number
CD4 + IL-2+ CD8 + IL-2+
Con SMO PRLR SMO Control SMO PRLR SMO
1 0 0 0 9.7
2 N 1.7 N 5.0
3 N 0.74 N 5.2
4 0 0 0 9.3
5 0 0.54 0 7.4
6 0.33 0.35 1.2 6.6
7 0 0 6.7 3.7
8 0 0 0 10
1/6 4/8 2/6 8/8*
N: not detected – animal died before predetermined sampling time.
* p < 0.01 compared to control CD8+ (Mann–Whitney test).
Fig. 3. Effect of the PRLR SMO on tumor-initiating cells and the primary tumor. Tumor-initiating cells were isolated from 4T1 cells and treated for 7 days in three-
dimensional culture (A and B). 50 μm was used as the criterion for a colony for quantiﬁcation. *p < 0.05. This assay was conducted 3 times. As an alternate analysis, 4T1
cells were treated for 15 days in two-dimensional culture and the number of cells with a stem cell phenotype was assessed by ﬂow cytometry (C). Results in panel C are
expressed as a percentage relative to day 0 and control SMO-treated. 70 × 103 cells were analyzed per sample. Panel D shows the results of treatment on stem cell marker
positive cells in three-dimensional culture. Results are expressed as the actual percentage of tumor-initiating cells in the population. The control SMO had no effect. For
this analysis, 1 × 106 cells were analyzed for all but the 15-day time point where an insuﬃciency of cells necessitated the use of 250 × 103 cells. Panel E shows a scatterplot
illustrative of apoptosis in the stem cell compartment after 15 days of treatment in three-dimensional culture. The dots have been enlarged to make them visible in this
format. The two-dimensional analysis was conducted once and the three-dimensional analysis two times. Tumors analyzed in panels F–H were induced by orthotopic place-
ment of 1 × 106 4T1 cells. Treatment was with vehicle, control SMO or PRLR SMO (100 pmol/h/mouse) for 14 days. Shown are both EdU and TUNEL staining of serial sections
from similarly-sized tumors (F) and quantiﬁcation of this staining (G). The EdU staining in panels 1–3 is green, as is the TUNEL staining in panels 4–6 to contrast with the
blue DAPI staining. After sizing to produce the composite, the contrast of all images was equally enhanced. Bars = 250 μm. Also shown is the effect on expression of PRLR LF
in the tumor on day 14 (H). n = 6 animals per group. *p < 0.05. In different time frames ranging from 3 to 40 days of treatment, the tumor EdU and TUNEL analyses were
conducted 5 times. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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[40]. Because these cells are not resistant to 6-thioguanine, a
more traditional morphometric analysis was employed to
determine metastatic spread. In this model, the PRLR SMO
inhibited metastasis by 75% after 25 days of treatment (Fig. 4A),
and, as a consequence, markedly improved the histological
appearance of the lungs and liver. Metastatic damage in the
livers and lungs of control animals was substantial (Fig. 4C and D),
showing patches of coagulative/liquifactive necrosis in the liver
and reduced air space in the lungs. Since the human PRLR SMO
had no effect on the expression of mouse PRLRs (determined
by quantitative RT-PCR of mouse tissues as for Fig. 1), we know
that the effects of the PRLR SMO in this model were initiated
via effects on tumor parenchyma. A much greater proportion
of BT-474 cells (and also T47D cells) expressed both PRL and
the PRLR. These human tumor cells were therefore much
more sensitive to the human PRLR SMO in vitro, with signiﬁcant in-
hibitory effects on cell number at 50 nM (Supplementary Fig. S2D
and E).
Lack of discernible toxicity
Because aminotransferases are cytoplasmic enzymes, elevated
levels are considered indicative of tissue, and mostly liver, damage.
Levels were assessed in plasma from both mouse strains both with
and without tumors. The levels were elevated when larger numbers
of tumor cells were implanted (Supplementary Fig. S4). None of the
SMOs (control or mouse or human PRLR) or lengths of treatment
raised levels above the normal range in the absence or presence of
tumor cells. The PRLR SMO had no signiﬁcant effect on levels of these
enzymes versus the control SMO (or saline vehicle in trials where
this group was present), but there was a trend toward decreased
levels of AST and ALT in the 25-day treatment of BT-474 im-
planted animals (Supplementary Fig. S4). This trend meshes well
with the improved morphological appearance of the liver from the
BT-474 PRLR SMO-treated animals. An assessment of potential effects
in non tumor-bearing animals on overall percentages of blood cells
or thymic or splenic content of CD4+ or CD8+ cells showed no effect
Fig. 4. Effect of the human PRLR SMO on lung and liver metastases from human BT-474 tumors. Tumors were initiated by orthotopic placement of 1 × 106 BT-474 cells.
Treatment was with control SMO or hPRLR SMO (100 pmol/h/mouse) for 25 days. Quantiﬁcation of metastatic spread was by morphometric analysis of lung sections (A).
Knockdown of the LF PRLR in the primary tumor at day 25 is also shown (B). Histopathological images from control (C and D) and PRLR SMO-treated (E and F) livers and
lungs. n = 6 animals per treatment. *p < 0.05. These analyses were conducted twice. Bar = 60 μm in C and E, 240 μm in D and F.
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of either the control SMO or PRLR SMO (Supplementary Table S1).
Histological examination of tissues of animals treated with the SMOs
for 28 days in the absence of tumors showed no effect on any tissue,
including the number of cells in the crypts of the small intestine
incorporating EdU (Supplementary Fig. S5). Observation of the mice
also showed no overt change in behavior, eating habits or change
in weight. Thus, we could discern no evidence of in vivo SMO toxicity.
Discussion
The results presented demonstrate the feasibility of speciﬁc
knockdown of the long PRLR in vivo. Success in knockdown allowed
us to examine the role of the long PRLR in the progression of two
highlymetastatic models of breast cancer. High ratios of long to short
PRLRs are expressed by breast cancer cells [22] and knockdown of
the long PRLR had a major impact on primary tumor cell viability,
stem cell survival, andmetastatic spread. At the same time, we found
no evidence of toxic effects in the liver, presumably because the
impact of knockdown of the long receptors was different in a tissue
where a preponderance of short receptors is normal [41]. Also, the
PRLR SMO was without effect on expression of the long receptor
in the pituitary. Thus, if used therapeutically, the PRLR SMO would
more speciﬁcally target breast cancer cells than agents having a
similar effect on all forms of the receptor. Tissue speciﬁcity in al-
ternative splicing is commonplace [30], suggesting that this concept
may hold for other alternatively-spliced targets important in cancer.
Since others have shown that it is the ratio of long to short re-
ceptors and not the absolute numbers of long receptors that is
important in the progression of breast cancer [22], one would also
anticipate that knockdown of only the long PRLR, while retaining
anti-proliferative and pro-differentiative signaling [1,2,21,25,26]
through the short receptor, would be more eﬃcacious than knock-
down or inhibition of all PRLR forms. However, this remains to be
directly demonstrated.
To achieve splicing modulation, we used DNA SMOs that were
derivatized by the addition of morpholino groups and octa-guanidine
dendrimers. The morpholino derivatization increases half-life in
serum and the octa-guanidine derivatization effects cell penetra-
tion [42]. Given the low dose required for substantial knockdown
in the ovary, liver, mammary gland and tumor, cell penetration
appears very eﬃcient.
To administer the SMOs, we employed a continuous delivery mo-
dality that eliminated the peaks and troughs of more traditional
modes of therapeutic delivery, thereby maximizing the therapeu-
tic value of the small doses delivered. Multiple platforms exist to
translate this to clinical delivery. In the work described, in which
animals were treated up to 43 days, the SMOs had no observable
toxic effects as a consequence of their oligonucleotide nature (there
was no evidence of a neutrophilic effect through toll-like receptor
activation), their cell-penetrating technology (cytoplasmic enzymes
were not elevated in the serum), or their effect on PRLRs (no toxic
effect in the liver and normal white blood cell composition). In
ongoing trials, mice have now been treated for more than 6months,
with no apparent ill effects. Oligonucleotide therapies using differ-
ent cell-penetrating technologies, higher doses, andmore traditional
approaches for delivery are currently in clinical trials for Duchenne
muscular dystrophy and other genetic disorders [43]. Thus, appli-
cation of the PRLR SMO to human disease states seems viable.
Our emphasis in this study was on in vivometastatic spread since
clinically this is most important. In both models, knockdown of the
long PRLR markedly inhibited metastasis. Inhibition of metastatic
spread may result from effects on stromal and immune cells, which
also express PRLRs [8,9,34,44,45], in addition to direct effects on
tumor parenchyma. In the 4T1 model, it is hard to determine the
relative roles of potential responding cell types, but because the
human PRLR SMO used in the xenograft model only affected
expression of human PRLR, we know that a major effect on metas-
tasis (at least in this model) was caused via direct actions on the
tumor cells themselves. That said, direct effects could include al-
terations in chemokine production and recruitment of innate
immune cells, which in turn could inﬂuence tumor cell behavior
[37]. Parenchyma-immune interactions are not normally presentwith
in vitro assessments. This may explain the apparent contradiction
between our results, in which a decrease in signaling through the
long PRLR decreased invasion, and results from in vitro studies from
another laboratory using the human breast cancer cell line, MDA-
MB-231, in which treatment with PRL and signaling through the long
PRLR reduced invasive characteristics [24].
In the syngeneic model, the results showed the PRLR SMO altered
immune inﬁltrates in metastatic sites, reducing innate immune cells,
such as neutrophils and macrophages, that mediate inﬂammatory
responses while increasing anti-tumor cytotoxic CD8+ cells. As-
suming translation to the human situation, this would result in even
more effective anti-tumor activity of the human PRLR SMO than we
could demonstrate in the xenograft model.
Although our main focus was on metastasis, examination of the
primary tumor that served as the source of the metastatic cells
showed that treatment with the PRLR SMO increased cell death in
the central region. What proportion of this death was caused by cy-
totoxic T cells versus effects on angiogenesis is unclear at present.
PRL is angiogenic, most likely acting through effects on both mi-
crovascular endothelial cells [46] and macrophages [47], both of
which express the long PRLR [46,48].
Of particular importance in the current data is the evidence that
the PRLR SMO reduced the number of tumor-initiating/cancer stem
cells. The PRLR SMO not only inhibited function in the sphere-
forming assay but also caused apoptosis in cells displaying stem cell
markers. This is, to our knowledge, the ﬁrst indication that target-
ing the PRLR (or more speciﬁcally the long PRLR) has the potential
to be curative.
Our focus in this study has been on breast cancer, but activa-
tion of long PRLRs has been shown to be important to progression
of other cancers, including ovarian, and prostate [1–3], suggesting
that the PRLR SMO could have broad therapeutic value.
We conclude that the long form of the PRLR is important to the
progression of breast cancer and that the PRLR SMO holds promise
as a very effective therapeutic, particularly for metastatic disease.
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